Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 764198 in Healthy Male Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design) and Effect of Food on the Relative Bioavailability of BI 764198 (Open-label, Randomised, Two-way Cross-over)
Latest Information Update: 05 Nov 2020
At a glance
- Drugs BI 764198 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
Most Recent Events
- 02 Nov 2020 Status changed from recruiting to completed.
- 23 Sep 2020 Planned End Date changed from 2 Oct 2020 to 8 Oct 2020.
- 23 Sep 2020 Planned primary completion date changed from 2 Oct 2020 to 8 Oct 2020.